Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate the pharmacokinetic characteristics of AG2304 in healthy subjects.
To evaluate the pharmacokinetic characteristics and safety profiles of AG2304 compared with coadministration AG23041 and AG23042 after a single oral dose administration in healthy Korean subjects under fasting conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A | Experimental | Period 1: Coadministration of AG23041 and AG23042, Period 2: AG2304 |
|
| Sequence B | Active Comparator | Period 1: AG2304, Period 2: Coadministration of AG23041 and AG23042 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AG2304 | Drug | AG2304, Single-dose Oral Administration |
| |
| Measure | Description | Time Frame |
|---|---|---|
| AUC | Area under the plasma concentration | Pharmacokinetic plasma samples collected over a 72-hour period |
| Cmax | Peak Plasma Concentration | Pharmacokinetic plasma samples collected over a 72-hour period |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AG23041 and AG23042 |
| Drug |
AG23041/AG23042, Single-dose Oral Administration |
|